Tell me everything I need to know before reading systemic pharmacology in very details (like every receptor and how does it work)

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

Searching Images

receptor types signal transduction G protein coupled ion channel enzyme linked

This pathophysiology diagram illustrates G-protein-coupled receptor (GPCR) signal transduction pathways across a plasma membrane. The schematic details four primary Gα subunit cascades. The Gαs pathway activates adenylate cyclase (AC) to convert ATP into cAMP, which stimulates Protein Kinase A (PKA). Conversely, Gαi/o inhibits AC, reducing cAMP and inhibiting PKA activity. The Gαq/11 pathway activates Phospholipase C (PLC), which cleaves PIP2 into diacylglycerol (DAG) and inositol triphosphate (IP3). DAG subsequently activates Protein Kinase C (PKC), while IP3 triggers calcium (Ca2+) release from the endoplasmic reticulum (ER) to serve as a second messenger. The Gα12/13 pathway is shown activating GTPases, involved in cytoskeleton and signal regulation. Additionally, the diagram depicts GPCR desensitization through arrestins and the dissociation of the Gβγ complex. The visual highlights the molecular mechanisms by which extracellular ligands regulate metabolic pathways, gene expression, and enzyme activity in human cellular physiology.

A pathophysiology diagram illustrating the signal transduction pathway of Group I metabotropic glutamate receptors (mGluRs). The visual depicts a serpentine G-protein-coupled receptor (GPCR) embedded in a gray horizontal bar representing the cell membrane. On the extracellular side, a red circle representing glutamate binds to the receptor complex. Intracellularly, the receptor is associated with a heterotrimeric G-protein complex consisting of beta (dark red), gamma (yellow), and alpha-q (pink) subunits. Upon activation, an arrow with a '+' symbol indicates the stimulation of phospholipase C (PLC), represented as a light blue oval. The pathway bifurcates from PLC, leading to 'Inositolphosphate turnover' and the production of inositol trisphosphate (IP3). IP3 is shown acting on an intracellular storage organelle (white circle) to trigger the release of calcium ions (Ca2+), labeled as increased 'Intracellular [Ca2+]'. This schematic summarizes the biochemical cascade from neurotransmitter binding to secondary messenger activation in neural signaling.

A pathophysiology diagram illustrating the RLR (RIG-I-like receptor) signaling pathway and its regulation by ubiquitination. The pathway originates in the cytoplasm where RIG-I and MDA5 recognize viral ligands and converge on the mitochondrial adaptor protein MAVS. Downstream signal transduction proceeds through a complex of TRAF3, IKKi, TANK, NEMO, and TBK1, leading to the phosphorylation of transcription factors IRF3 and IRF7. These factors translocate from the cytoplasm into the nucleus to initiate Type I Interferon (IFN-I) production. The diagram highlights the extensive regulatory role of E3 ubiquitin ligases and deubiquitinating enzymes (DUBs), listed in blue boxes adjacent to key signaling proteins (RIG-I, MDA5, MAVS, and STING). It specifies various ubiquitin linkage types (K63, K48, K27, K11, and linear) associated with specific regulators such as TRIM25, RNF125, and various USPs. K63-linked chains generally promote signaling activation, while K48-linked chains typically lead to proteasomal degradation for pathway attenuation. This visual serves as a comprehensive educational map for innate antiviral immunity and post-translational protein modification.

I now have everything I need from the textbooks. Let me compile the comprehensive answer.

Everything You Need to Know Before Reading Systemic Pharmacology

This is your complete foundational framework - receptor biology, pharmacodynamics, and pharmacokinetics - drawn from Katzung's Basic and Clinical Pharmacology, 16th Edition (Chapters 1 & 2).

1. What Is Pharmacology?

Pharmacology = the study of substances that interact with living systems through chemical processes, usually by binding to regulatory molecules and activating or inhibiting normal body processes.

Two major branches:

Pharmacokinetics - what the body does to the drug (absorption, distribution, metabolism, elimination)
Pharmacodynamics - what the drug does to the body (receptor binding, mechanism, effect)

2. Drug Properties

Size

Most drugs: MW 100-1000
Below 100 MW = too small to bind with specificity
Above 1000 MW = too large to diffuse between body compartments (must be given IV or directly at site)
Large biologics (antibodies, proteins) often >100,000 MW

Drug-Receptor Bond Types

Three types of bonds form between drugs and receptors:

Bond Type	Strength	Reversibility	Example
Covalent	Very strong	Usually irreversible	Aspirin + COX (platelet); DNA alkylating agents
Electrostatic	Moderate	Reversible	Most drug-receptor interactions (ionic, hydrogen bonds, van der Waals)
Hydrophobic	Weak	Reversible	Lipid-soluble drugs in membrane "pockets"

Key insight: Weak bonds = higher selectivity - the drug must fit its receptor very precisely. Strong covalent bonds are less selective.

Drug Shape

Shape must be complementary to the receptor (like a key fitting a lock). Chirality matters - most drugs are racemic mixtures, but the two enantiomers can have very different receptor affinities, potencies, and even different effects.

Ionization (Henderson-Hasselbalch)

Most drugs are weak acids or bases
Ionized form = water-soluble, cannot cross lipid membranes
Un-ionized form = lipid-soluble, crosses membranes freely

Henderson-Hasselbalch equation:

pH = pKa + log([ionized]/[un-ionized]) for bases

For a weak acid (like aspirin, pKa 3.5):

In stomach (pH 1-2): mostly un-ionized → absorbed
In blood (pH 7.4): mostly ionized → trapped

Ion trapping: Alkalinizing the urine (sodium bicarbonate) ionizes weak acid drugs → traps them in urine → increases renal elimination (this is why NaHCO₃ is given in aspirin overdose).

3. Drug Permeation Across Membranes

Four mechanisms:

Aqueous diffusion - through water-filled channels (pores) in endothelium; small polar molecules
Lipid diffusion - the most important for most drugs; depends on lipid:water partition coefficient
Special carriers (transporters) - active or facilitated transport; for molecules too polar to diffuse (eg, glucose, amino acids, organic acids)
Endocytosis/exocytosis - for very large molecules (eg, vitamin B12-intrinsic factor complex, iron-transferrin)

Fick's Law of Diffusion:

Flux = (Area × Permeability coefficient × [C1-C2]) / Thickness

4. The Receptor Concept - Core Foundation

A receptor is the macromolecule in a cell or organism that interacts with a drug and initiates the chain of events leading to the drug's observed effects.

Receptors serve two fundamental functions:

Ligand binding - recognition and binding of the drug/signal
Signal transduction - converting binding into a cellular response

Receptors are primarily proteins - cell surface or intracellular. Some important drug targets are not traditional "receptors" but enzymes (aspirin/COX), ion channels (local anesthetics/Na channels), transport proteins (SSRIs/serotonin transporter), or structural proteins.

5. The Four Major Receptor Families

Type 1: Ligand-Gated Ion Channels (Ionotropic Receptors)

Structure: Receptor IS the ion channel - ligand binds and directly opens/closes the channel
Speed: Milliseconds (fastest)
Location: Cell surface
Mechanism: Conformational change opens pore → ion flow → membrane potential change
Examples:

Receptor	Ion	Effect
Nicotinic ACh (nAChR)	Na⁺ in / K⁺ out	Depolarization (excitatory)
GABA-A	Cl⁻ in	Hyperpolarization (inhibitory)
Glycine	Cl⁻ in	Hyperpolarization (inhibitory)
NMDA (glutamate)	Na⁺, Ca²⁺ in	Excitatory, LTP
AMPA (glutamate)	Na⁺, K⁺	Fast excitatory
5-HT3 (serotonin)	Na⁺, K⁺	Excitatory

Drug targets: Benzodiazepines (modulate GABA-A), succinylcholine/d-tubocurarine (nAChR), memantine (NMDA)

Type 2: G Protein-Coupled Receptors (GPCRs) / Metabotropic

Structure: 7 transmembrane (7-TM) helical domains; largest receptor superfamily in the human genome (~800 genes)
Speed: Seconds to minutes
Mechanism: Ligand binds → activates G protein (trimeric: Gα, Gβ, Gγ) → Gα dissociates → acts on effectors (enzymes or ion channels)

G protein subtypes and their effectors:

G Protein	Second Messenger / Effect	Examples
Gs	↑ Adenylyl cyclase → ↑ cAMP → ↑ PKA	β1-AR (heart), β2-AR (bronchi), D1 receptor, H2 receptor
Gi	↓ Adenylyl cyclase → ↓ cAMP	M2 muscarinic, D2, α2-AR, opioid (μ,δ,κ)
Gq/G11	↑ Phospholipase C → ↑ IP3 + DAG → ↑ Ca²⁺ + PKC	M1, M3, M5, α1-AR, H1, AT1
G12/13	Activates Rho GTPases → cytoskeleton	Thrombin, LPA receptors
Gβγ (free subunit)	Directly opens GIRK K⁺ channels	M2 → K⁺ channel → slows SA node

Second messenger cascade:

cAMP pathway: Receptor → Gs → Adenylyl cyclase → ATP → cAMP → PKA activation → phosphorylation of proteins (eg, L-type Ca²⁺ channels, glycogen phosphorylase)
IP3/DAG pathway: Receptor → Gq → PLC-β → PIP2 → IP3 (releases ER Ca²⁺) + DAG (activates PKC)

Type 3: Enzyme-Linked Receptors (Receptor Tyrosine Kinases / RTKs)

Structure: Single transmembrane domain; extracellular ligand-binding domain + intracellular kinase domain
Speed: Minutes to hours
Mechanism: Ligand binds → receptor dimerization → autophosphorylation on tyrosine residues → recruits adaptor proteins → activates downstream cascades (MAPK/ERK, PI3K/Akt, JAK/STAT)
Examples:

Receptor	Ligand	Signaling
Insulin receptor	Insulin	Tyrosine kinase → PI3K/Akt → GLUT4 translocation
EGF receptor	EGF	Tyrosine kinase → MAPK/ERK → cell growth
VEGF receptor	VEGF	Angiogenesis
Cytokine receptors (JAK-STAT)	Interferons, EPO, IL-6	JAK phosphorylates STAT → gene transcription

Drug targets: Imatinib (BCR-ABL tyrosine kinase), trastuzumab (HER2), erlotinib (EGFR)

Type 4: Intracellular (Nuclear) Receptors

Location: Cytoplasm or nucleus
Ligands: Lipid-soluble small molecules that diffuse through the plasma membrane
Speed: Hours to days (must synthesize new proteins)
Mechanism: Ligand binds receptor → releases inhibitory protein (eg, hsp90 for glucocorticoid receptor) → receptor dimerizes → translocates to nucleus → binds DNA response elements → activates/represses gene transcription

Two-step mechanism for glucocorticoids:

Steroid diffuses into cell
Binds GR → hsp90 dissociates → GR dimerizes → enters nucleus → binds GRE (glucocorticoid response element) → mRNA synthesis

Ligand	Receptor	Effect
Glucocorticoids	GR	Anti-inflammatory gene expression
Mineralocorticoids	MR	Sodium retention genes
Sex steroids	AR, ER, PR	Secondary sex characteristics, reproduction
Thyroid hormone (T3)	TR	Metabolic rate
Vitamin D	VDR	Calcium homeostasis genes
Retinoids	RAR, RXR	Differentiation, growth

Clinical consequence: Glucocorticoids do NOT relieve asthma immediately - there is a lag of 30 min to several hours for new protein synthesis.

6. Receptor Regulation

Desensitization / Tachyphylaxis / Down-regulation:

Prolonged agonist exposure → receptor phosphorylation by GRKs → β-arrestin binding → receptor internalization (endocytosis) → fewer surface receptors → reduced response
Example: Prolonged β2-agonist use in asthma → tachyphylaxis

Supersensitivity / Up-regulation:

Prolonged antagonist exposure → more receptors synthesized → exaggerated response if antagonist suddenly withdrawn
Example: β-blocker withdrawal → rebound tachycardia/hypertension

7. Dose-Response Relationships

Graded Dose-Response Curves

Plotted as effect (%) vs log[drug concentration]
Sigmoidal shape

Key parameters:

EC50 (ED50): Concentration producing 50% of maximal effect - measures potency
Emax: Maximal effect achievable - measures efficacy
Hill coefficient (n): Slope of the curve; indicates cooperativity

Potency ≠ Efficacy: A drug can be very potent (low EC50) but have low efficacy (low Emax), or vice versa. Clinically, efficacy matters more than potency.

Agonists vs Antagonists

Term	Definition	Effect on curve
Full agonist	Produces maximal response at full receptor occupancy	Emax = 100%
Partial agonist	Intrinsic activity < 1; can't produce Emax even at 100% occupancy	Emax < 100% (can act as antagonist in presence of full agonist)
Inverse agonist	Binds receptor, produces opposite effect to agonist	Drives receptor to inactive state
Competitive antagonist	Binds same site as agonist, reversibly; shifts curve right	↑ EC50, same Emax
Irreversible/non-competitive antagonist	Binds irreversibly or allosteric site; can't overcome with more drug	↓ Emax
Physiologic antagonist	Two drugs with opposite physiologic effects (different receptors)

Spare receptors (receptor reserve): Maximum effect can occur when only a fraction of receptors are occupied. This means EC50 < Kd (the dissociation constant). Important for: understanding why partial agonists can block full agonists in tissues with spare receptors.

8. Quantal Dose-Response & Therapeutic Index

Quantal curves plot the frequency of an all-or-none response (eg, % of population that responds) vs log dose.

ED50: Dose effective in 50% of population
LD50: Dose lethal in 50% of population (animal data)
TD50: Dose producing a toxic effect in 50% of population

Therapeutic Index (TI) = TD50 / ED50

Higher TI = safer drug
Example: Digoxin has a narrow TI (toxic dose close to therapeutic dose)

Certain Safety Factor = TD1 / ED99 (more clinically useful; avoids any toxicity)

9. Pharmacokinetics Essentials

ADME

Absorption - rate and extent drug enters systemic circulation
- Bioavailability (F): Fraction of dose reaching systemic circulation
- Affected by: first-pass metabolism, solubility, formulation
Distribution
- Volume of distribution (Vd): Apparent volume needed to contain total drug at same concentration as plasma
- Small Vd = stays in plasma (eg, warfarin); Large Vd = distributes widely into tissues (eg, chloroquine)
- Blood-brain barrier: only lipid-soluble, un-ionized drugs cross
- Protein binding (albumin, α1-acid glycoprotein): only FREE drug is active
Metabolism
- Phase I: CYP450 enzymes - oxidation, reduction, hydrolysis → add/expose functional groups
- Phase II: Conjugation (glucuronidation, sulfation, acetylation, methylation) → increase polarity for excretion
- First-pass effect: oral drug metabolized in gut wall and liver before reaching systemic circulation
Elimination
- Renal: Filter + secrete (active) + reabsorb; affected by pH, protein binding
- Hepatic: Biliary excretion; enterohepatic cycling

Key PK Parameters

Half-life (t½) = 0.693 × Vd / CL (CL = clearance)
After 4-5 half-lives: drug reaches steady-state (if dosed repeatedly) OR drug is 97% eliminated
Clearance (CL): Volume of plasma cleared per unit time; most important PK parameter for dosing
Zero-order kinetics: Fixed amount eliminated per unit time (saturable; eg, alcohol, phenytoin at high doses) - dangerous nonlinear behavior
First-order kinetics: Fixed fraction eliminated per unit time (most drugs)

10. The Autonomic Nervous System - The Most-Tested Receptor System

Before systemic pharmacology, you must know the ANS cold:

Sympathetic (Adrenergic) Receptors

Receptor	Location	G protein	Effect	Key Agonists/Antagonists
α1	Vascular smooth muscle, bladder, eye	Gq → IP3/DAG → ↑Ca²⁺	Vasoconstriction, mydriasis, urinary retention	Agonist: phenylephrine; Antagonist: prazosin, tamsulosin
α2	Presynaptic (autoreceptor), pancreatic β-cells	Gi → ↓cAMP	↓NE release (negative feedback), ↓insulin	Agonist: clonidine; Antagonist: yohimbine
β1	Heart (SA node, AV node, ventricle)	Gs → ↑cAMP	↑HR, ↑contractility, ↑conduction	Agonist: dobutamine; Antagonist: metoprolol
β2	Bronchial smooth muscle, vascular SM, uterus	Gs → ↑cAMP	Bronchodilation, vasodilation, uterine relaxation	Agonist: salbutamol; Antagonist: propranolol (non-selective)
β3	Adipose tissue	Gs → ↑cAMP	Lipolysis, thermogenesis	Agonist: mirabegron (bladder)
DA1 (dopamine)	Renal/mesenteric vasculature	Gs → ↑cAMP	Vasodilation (renal protective)	Agonist: low-dose dopamine
DA2	Presynaptic (autoreceptor)	Gi	↓NE/DA release

Parasympathetic (Cholinergic) Receptors

Muscarinic Receptors (GPCRs):

Receptor	Location	G protein	Effect
M1	CNS, gastric parietal cells, ganglia	Gq	↑Gastric acid (PLC pathway), cognitive function
M2	Heart (SA, AV nodes)	Gi + Gβγ → GIRK K⁺ channel	↓HR (bradycardia), ↓AV conduction
M3	Smooth muscle (GI, bladder, bronchi), glands, eye	Gq	Contraction, secretion, miosis, accommodation
M4	CNS, striatum	Gi	Modulates dopamine
M5	CNS, dopaminergic neurons	Gq	Modulates reward pathway

Muscarinic signaling diagram:

Nicotinic Receptors (Ligand-gated ion channels - Type 1):

Receptor	Location	Effect
NM (muscle type)	Neuromuscular junction	Na⁺ influx → depolarization → muscle contraction
NN (neuronal type)	Autonomic ganglia (both sympathetic and parasympathetic), CNS, adrenal medulla	Fast EPSP → preganglionic to postganglionic transmission

11. Neurotransmitter Synthesis, Release, and Termination

Catecholamine Synthesis Pathway

Tyrosine → DOPA → Dopamine → Norepinephrine → Epinephrine

Rate-limiting step: Tyrosine hydroxylase (Tyrosine → DOPA)
Conversion to epinephrine occurs only in adrenal medulla (PNMT enzyme, induced by cortisol)

Termination of Catecholamine Action

Neuronal reuptake (NET/DAT) - most important; ~80% of NE reuptake by NET1
MAO (monoamine oxidase) - intracellular degradation
COMT (catechol-O-methyltransferase) - extracellular methylation
Diffusion away from synapse

ACh Synthesis and Termination

Synthesis: Choline + Acetyl-CoA → ACh (by choline acetyltransferase, ChAT)
Termination: Acetylcholinesterase (AChE) - hydrolyzes ACh → choline + acetate; choline recycled

12. Signal Transduction Second Messengers - Quick Reference

Second Messenger	Produced by	Degraded by	Key Effects
cAMP	Adenylyl cyclase (from ATP)	Phosphodiesterase (PDE)	Activates PKA → phosphorylates proteins (eg, ↑HR, ↑glycogenolysis)
cGMP	Guanylyl cyclase	PDE5	Activates PKG → smooth muscle relaxation (NO pathway)
IP3	PLC-β cleaves PIP2	Phosphatase	Releases Ca²⁺ from ER/SR
DAG	PLC-β cleaves PIP2	DAG kinase	Activates PKC → protein phosphorylation
Ca²⁺	Released from ER (IP3) or via VGCC	SERCA pump, Na/Ca exchanger	Activates calmodulin → CaMKII → smooth/cardiac muscle contraction
Arachidonic acid	PLC-A2 liberates from membrane	-	Prostaglandins (COX), leukotrienes (LOX)

13. Drugs That Don't Work Through Receptors

Not all drugs bind traditional receptors:

Antacids (Mg(OH)₂) - direct acid neutralization
Osmotic diuretics (mannitol) - osmotic effect
Chelating agents - bind metal ions
Some antiseptics - denature proteins nonspecifically
Volatile anesthetics - dissolve in neuronal membranes (Meyer-Overton theory)

14. Key Concepts You'll See Constantly in Systemic Pharmacology

Concept	Definition
Therapeutic window	Range between minimum effective concentration and minimum toxic concentration
Loading dose	Large initial dose to rapidly reach therapeutic concentration = Vd × target Cp
Maintenance dose	Dose to maintain steady state = CL × target Cp
Tachyphylaxis	Rapid tolerance with repeated dosing
Tolerance	Reduced response over time (pharmacodynamic or pharmacokinetic)
Synergism	Combined effect > additive
Antagonism	Combined effect < additive
Drug interaction	Pharmacokinetic (CYP450) or pharmacodynamic

15. The Most Important CYP450 Facts

CYP3A4: metabolizes ~50% of all drugs (inducers: rifampicin, carbamazepine, phenytoin; inhibitors: ketoconazole, erythromycin, grapefruit juice)
CYP2D6: genetic polymorphism; poor metabolizers have toxicity from codeine → morphine conversion
CYP2C9: warfarin, NSAIDs (inhibitor: fluconazole → warfarin toxicity)
CYP2C19: omeprazole, clopidogrel (poor metabolizers → clopidogrel fails)
CYP1A2: theophylline, caffeine (induced by smoking)

Summary: The Big Picture Before Systemic Pharmacology

Drug administered
      ↓ (Pharmacokinetics: ADME)
Drug reaches receptor
      ↓ (Pharmacodynamics: receptor binding)
Receptor activated/inhibited
      ↓ (Signal transduction)
Second messengers / gene expression
      ↓
Cellular response (physiologic effect)
      ↓
Clinical outcome (therapeutic or toxic)

The four receptor superfamilies are the skeleton on which all systemic pharmacology hangs:

Ion channels (Type 1): Fastest, ANS ganglia/NMJ, GABA, glutamate
GPCRs (Type 2): Largest family, most drug targets, all adrenergic/muscarinic/opioid/histamine receptors
RTKs (Type 3): Insulin, growth factors, cytokines
Nuclear receptors (Type 4): Steroids, thyroid hormone - slowest, gene-level effects

Every drug chapter you read will map back to: which receptor, which G protein (or not), which second messenger, which protein gets phosphorylated, what is the clinical effect.

Sources: Katzung's Basic and Clinical Pharmacology, 16th Edition, Chapters 1 & 2 - "The Nature of Drugs" and "Drug Receptors & Pharmacodynamics"

This is a shared conversation. Sign in to Orris to start your own chat.